Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.90
- Piotroski Score 4.00
- Grade Sell
- Symbol (RDUS)
- Company Radius Health, Inc.
- Price $18.57
- Changes Percentage (-2.55%)
- Change -$0.49
- Day Low $18.34
- Day High $19.07
- Year High $31.70
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
- Last Earnings 07/02/2024
- Ex-Dividend for 5/16 Dividend 07/22/2024
- Dividend Payable 08/05/2024
- Today N/A
- Next Earnings (Estimated) 10/24/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.26
- Trailing P/E Ratio -7.04
- Forward P/E Ratio -7.04
- P/E Growth -7.04
- Net Income $-25,791,000
Income Statement
Quarterly
Annual
Latest News of RDUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The recent 108% gain must have brightened CEO Roshan Pujari's week, Stardust Power Inc.'s (NASDAQ:SDST) most bullish insider
Analyzing a company's past performance and ownership data can provide insights into its future prospects. Stardust Power Inc.'s shareholder groups include individual insiders holding 45% of shares, in...
By Yahoo! Finance | 2 months ago -
The past three years for Radius Recycling (NASDAQ:RDUS) investors has not been profitable
Investing in Radius Recycling, Inc. has been challenging with a 68% decline in share price over three years. Despite recent gains, long-term shareholders have faced losses due to the company's declini...
By Yahoo! Finance | 2 months ago -
Nardus Williams/Elizabeth Kenny review - compelling and crystalline duo open Spitalfields festival
In the historic Chapel of St Peter ad Vincula at the Tower of London, rising-star soprano Nardus Williams and uber-lutenist Elizabeth Kenny performed a captivating concert blending songs from the Tudo...
By The Guardian | 3 months ago
